ClinicalTrials.gov
public full text
Public Domain
Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab
The purpose of this study is to determine whether teplizumab slows the loss of β cells and preserves β cell function in children and adolescent 8-17 years old who have been diagnosed with T1D in the previous 6 weeks.. Subjects will receive two courses of either teplizumab or placebo treatment 6 months apart.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes#916488
- Efficacy and Safety ofSanGrow Decoction for Patients With Diabetes#1047338
- Safety and Efficacy of Saxagliptin in Triple Therapy to Treat Subjects With Type 2 Diabetes#287492
- Group Education Trial to Improve Transition in Type 1 Diabetes#1047839
- Type 1 Diabetes Data Acquisition and Transfer Adherence Study#840116
Record · ID 1032390
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive